The Development of a PdCr Integral Weldable Strain Measurement System Based on NASA Lewis PdCr/Pt Strain Sensor for User-Friendly Elevated Temperature Strain Measurements

This report describes the development of a user friendly weldable strain gage employing the NASA Lewis PdCr/Pt wire strain sensor. The NASA sensors are pre-attached to Hastelloy X or Titanium alloy shims using name spray techniques developed under previous NASA programs. The weldable sensors are then pre-stabilized for 50 hours at 780 C in air. A weldable terminal and high temperature cable is then connected to the sensor and the assembly is pre-calibrated over the full test temperature range. Calibrated resistors are inserted into a bridge completion module at the cool end of the cable to condition the sensor in half or full bridge configuration. The sensor is attached to the structure using a common capacitive discharge spot welder. No additional high temperature stabilization or calibration is required. The resultant device is a pre-calibrated strain transducer which can be plugged into any common variety strain instrumentation

Procedure for Installation of PdCr Gages by Flame Spraying

This document contains the installation procedure employed under NASA contract NAS3-27038. They represent the state of the art at the time of this project

As light as your scent: effects of smell and sound on body image perception

How people mentally represent their body appearance (i.e., body image perception - BIP) does not always match their actual body. BIP distortions can lead to a detriment in physical and emotional health. Recent works in HCI have shown that technology can be used to change people’s BIP through visual, tactile, proprioceptive, and auditory stimulation. This paper investigates, for the first time, the effect of olfactory stimuli, by looking at a possible enhancement of a known auditory effect on BIP.We present two studies building on emerging knowledge in the field of crossmodal correspondences. First, we explored the correspondences between scents and body shapes. Then, we investigated the impact of combined scents and sounds on one’s own BIP. Our results show that scent stimuli can be used to make participants feel lighter or heavier (i.e., using lemon or vanilla) and to enhance the effect of sound on perceived body lightness. We discuss how these findings can inform future research and design directions to overcome body misperception and create novel augmented and embodied experiences

Research achievements in plant resistance to insect pests of cool season food legumes

Plant resistance to at least 17 field and storage insect pests of cool season food legumes has been identified. For the most part, this resistance was located in the primary gene pools of grain legumes via conventional laboratory, greenhouse, and field screening methods. The use of analytical techniques (i.e., capillary gas chromatography) to characterize plant chemicals that mediate the host selection behavior of pest insects offers promise as a new, more rapid way to differentiate between insect-resistant and susceptible plant material. Examples of research achievements in mechanisms of resistance and host-plant resistance within the context of integrated control programs are discussed. Accelerating the development and subsequent releases of insect-resistant cultivars to pulse farmers requires more involvement from interdisciplinary teams of plant breeders, entomologists, plant pathologists, plant chemists, molecular biologists, and other scientist

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570